Since its identification in 2001, human metapneumovirus (hMPV) has been recognised as a cause of respiratory illness across paediatric and adult populations (Human Metapneumovirus (hMPV) Infection, 2025). However, hMPV remains less well understood than other major respiratory viruses such as Respiratory Syncytial Virus (RSV) or influenza. Important gaps remain in the knowledge around its prevalence, the populations most affected, and its impact on healthcare systems.
Part of the challenge is that hMPV results in symptoms that resemble other respiratory tract infections (RTIs), including fever, cough, runny nose and congestion. Diagnostic testing is therefore necessary to establish a precise diagnosis and generate the data needed to quantify the overall burden of hMPV (Human Metapneumovirus (hMPV) Infection, 2025b).
Not long ago, RSV faced similar challenges. Researchers knew the virus was causing significant illness, particularly among vulnerable populations, but accurately quantifying its burden was difficult. Testing practices varied between healthcare settings, and respiratory infections were often recorded using non-specific diagnoses. Research was also frequently based on relatively small or local patient populations (Duan et al., 2025). As a result, important questions around incidence, healthcare utilisation and disease burden took years to answer.
Over time, improved testing, surveillance and access to larger datasets helped change that picture. Today, the evidence base for RSV provides a much clearer understanding of its impact on patients and healthcare systems, which helps inform prevention strategies. For hMPV, this experience provides a valuable starting point.
It is already known that hMPV can affect people of all ages and can cause severe disease, particularly among young children, older adults and immunocompromised individuals (Infectious Disease Advisor, 2026). Recent research also suggests that its impact in adults could be comparable with RSV on measures such as symptom burden and disruption to work (Bassiouni et al., 2025).
While these findings provide important insights into the impact of hMPV, the broader picture across different populations and healthcare systems is not yet fully understood. Several challenges, many of which were also seen with RSV, continue to limit the knowledge available on hMPV:
As mentioned earlier, research into respiratory infectious diseases has evolved significantly over the past decade, supported by advances in surveillance, testing and real-world evidence (RWE) generation. These advances create an opportunity to apply lessons learned from other respiratory pathogens to hMPV. This is particularly relevant as hMPV vaccine development progresses. As this field advances, robust evidence will become increasingly important to support future decision-making. Building that evidence base starts with answering several key questions:
Although hMPV is not a new virus, important clinical-related knowledge gaps remain. The tools available to study its burden have evolved considerably. The data and methods developed through years of respiratory disease research can help answer the questions above and close the knowledge gaps faster than in the past. RWE studies can contribute to this by extending the evidence beyond selected patient populations or individual healthcare settings. This broader perspective can provide a more comprehensive picture of hMPV and its impact.
The LOGEX Respiratory Tract Infection (RTI) Observatory builds on this approach and has supported, and continues to support, research into the burden and impact of RSV across multiple European countries. Importantly, its scope extends to other respiratory pathogens as well, including hMPV, which allows key gaps in the knowledge around its burden to be adressed. It also enables hMPV to be studied in the wider context of RTIs, alongside RSV, influenza, PIV3 and other respiratory pathogens. This broader perspective can help put its burden into context and identify differences across patient populations and healthcare systems.
Looking to better understand the impact of hMPV? Get in touch with our team to explore how the LOGEX RTI Observatory can support your research.
Bassiouni, S. S., Foster-Tucker, J. E., Callear, A. P., Godonou, E., Smith, M., Johnson, E., Martin, E. T., & Monto, A. S. (2025). A comparative profile of the burden of human metapneumovirus, respiratory syncytial virus, and influenza in the HIVE cohort, 2010–2022. The Journal of Infectious Diseases, 232(Supplement_1), S101–S108. https://doi.org/10.1093/infdis/jiaf113
Duan, Q., Pan, J., Zheng, L., Jin, Z., Li, S., Zhang, H., Fu, X., Chen, R., Yu, Z., Qin, S., Xu, X., Chen, Y., Sun, J., & Liu, S. (2025). Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: a systematic review and meta-analysis. EClinicalMedicine, 86, 103352. https://doi.org/10.1016/j.eclinm.2025.103352
Human metapneumovirus (hMPV) infection. (2025, 27 november). https://www.who.int/news-room/questions-and-answers/item/human-metapneumovirus-(hmpv)-infection
Human metapneumovirus (hMPV) infection. (2025b, November 27). https://www.who.int/news-room/questions-and-answers/item/human-metapneumovirus-(hmpv)-infection
Infectious Disease Advisor. (2026, March 25). Human Metapneumovirus | Diagnosis & Disease Information. https://www.infectiousdiseaseadvisor.com/ddi/human-metapneumovirus/